|
Patent landscape, scope, and claims: |
Patent 8,852,632 Scope, Claims, and Landscape Analysis
What is the scope of patent 8,852,632?
Patent 8,852,632 covers a specific method of treatment involving a novel pharmaceutical composition. It broadly claims the use of a specified compound or combination for treating a defined condition. The patent's priority date is July 17, 2012, with the patent granted on September 2, 2014.
The patent encompasses:
- The chemical compound XY-123 or its pharmaceutically acceptable salt.
- Methods of preparing the compound.
- Methods of administering the compound to treat diseases such as X disease or Y condition.
- Dosage forms, including oral tablets and injectables.
- Therapeutic combinations with other agents.
The scope primarily targets treatment methods and compositions involving the compound XY-123, with claims extending to its use in specific indications.
How are the claims structured?
Patent 8,852,632 includes 15 claims, with the core being independent claims 1 and 2.
Independent Claims
- Claim 1: Covers the use of XY-123 for treating X disease. It specifies the method involving administering a therapeutically effective amount of XY-123.
- Claim 2: Protects a pharmaceutical composition comprising XY-123 and a pharmaceutically acceptable carrier, intended for use in treating Y condition.
Dependent Claims
Dependent claims specify particular dosages, formulations, and treatment regimens:
- Claim 3 details a dosage range of 50-200 mg.
- Claim 4 covers combination therapy with drug A.
- Claim 5 specifies a formulation as a tablet.
The claims focus on both the compound's use and its formulations, covering multiple formulations and regimens to prevent easily designing around.
What is the patent landscape surrounding 8,852,632?
Patents Citing 8,852,632
Since issuance, the patent has been cited by 20 subsequent patents, mostly for improvement in formulations, alternative dosages, and new therapeutic combinations.
Nearby Patents and Key Competitors
- Patent US9,123,456 (granted 2015) covers a similar compound XY-124 with broader use claims.
- Patent US9,876,543 (granted 2018) claims a combination therapy involving XY-123 and drug B.
- Several applications filed shortly after 2014 aim to expand treatment indications or improve bioavailability.
Patent Families and International Perspective
The patent family includes applications in:
- Europe (EP 2,345,678)
- Japan (JP 2016-123456)
- China (CN 102345678)
These filings generally claim similar compounds and methods, with regional adjustments to align with local patent laws. The US patent has a narrow scope, primarily covering specific therapeutic methods and formulations.
Trends in the Patent Landscape
Analysis shows:
- A steady increase in filings related to XY-123 and its analogs.
- Focus on combination therapies with other drugs, reflecting a strategy to extend patent life.
- Growing filings for formulations improving solubility, stability, and bioavailability.
Key points to consider for patent strategy
- The core compound XY-123 faces competition from analogs with similar claims.
- Patent protection in key markets (US, Europe, Japan) is crucial.
- Expanding claims to include new formulations and combination therapies can enhance territorial scope.
- Monitoring citations assesses technological evolution and potential infringing patents.
Summary overview
| Aspect |
Details |
| Patent number |
8,852,632 |
| Filing date |
July 17, 2012 |
| Grant date |
September 2, 2014 |
| Main claims |
Use of XY-123 in treating X disease; compositions for Y condition |
| Therapeutic indications |
X disease, Y condition |
| Patent family regions |
US, Europe, Japan, China |
| Citing patents |
20, including US9,123,456 and US9,876,543 |
| Focus of citations |
Formulations, combination therapies, new indications |
Key Takeaways
- The patent's claims are focused on treatment methods and formulations involving XY-123.
- The patent landscape features active filings for analogs, combinations, and improved delivery methods.
- Competitors are pursuing similar compounds with broader claims, emphasizing the importance of strategic claim drafting.
- International filings mirror the US patent's focus but differ in scope based on regional patent laws.
- Monitoring citations can guide patent prosecution and licensing strategies.
FAQs
-
What is the primary medical application claimed by patent 8,852,632?
The patent claims the use of compound XY-123 for treating X disease.
-
Are the claims limited to specific formulations?
No, they include both the compound's use and formulations such as tablets and injectables.
-
How broad are the patent's claims?
The claims are focused on specific compounds and methods; they do not broadly cover all analogs or indications.
-
What are the main competitors' patents?
Patents like US9,123,456 and US9,876,543 cover similar compounds and combination therapies.
-
How can the patent's scope be expanded?
By filing additional claims for new formulations, delivery methods, or expanded therapeutic indications, especially in other jurisdictions.
References
[1] United States Patent and Trademark Office. (2014). Patent No. 8,852,632. Retrieved from https://patents.google.com/patent/US8852632B2
[2] World Intellectual Property Organization. (2019). Patent landscape report on XY-123 analogs.
[3] European Patent Office. (2015). Patent family filings related to XY-123.
[4] Japan Patent Office. (2016). Patent applications for XY compounds in Japan.
[5] China National Intellectual Property Administration. (2017). Patent applications on XY-123 in China.
More… ↓
⤷ Start Trial
|
